Shares of NovoCure Limited (NASDAQ:NVCR – Get Free Report) have earned an average recommendation of “Hold” from the eight ratings firms that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, four have issued a hold rating and three have given a buy rating to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $22.33.
Several equities analysts have recently weighed in on NVCR shares. Wells Fargo & Company cut their target price on NovoCure from $20.00 to $15.00 and set an “equal weight” rating on the stock in a research report on Friday, October 30th. Wall Street Zen raised shares of NovoCure from a “hold” rating to a “buy” rating in a report on Saturday, October 31st. Zacks Research raised shares of NovoCure from a “strong sell” rating to a “hold” rating in a research report on Friday, July 24th. Weiss Ratings lowered NovoCure from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, October 30th. Finally, Wedbush lowered their price objective on NovoCure from $20.00 to $19.00 and set a “neutral” rating for the company in a research report on Tuesday, November 10th.
Get Our Latest Stock Analysis on NovoCure
Hedge Funds Weigh In On NovoCure
Several hedge funds have recently modified their holdings of NVCR. Jump Financial LLC grew its stake in NovoCure by 10.4% during the 3rd quarter. Jump Financial LLC now owns 343,870 shares of the medical equipment provider’s stock valued at $5,485,000 after purchasing an additional 32,521 shares during the last quarter. EP Wealth Advisors LLC lifted its holdings in shares of NovoCure by 27.8% during the third quarter. EP Wealth Advisors LLC now owns 14,709 shares of the medical equipment provider’s stock worth $235,000 after purchasing an additional 3,198 shares during the period. First Trust Advisors LP lifted its holdings in shares of NovoCure by 164.9% during the third quarter. First Trust Advisors LP now owns 335,392 shares of the medical equipment provider’s stock worth $5,350,000 after purchasing an additional 208,796 shares during the period. TIAA CREF Individual & Institutional Services LLC purchased a new stake in NovoCure in the third quarter valued at approximately $132,000. Finally, Ieq Capital LLC increased its holdings in NovoCure by 24.3% in the 3rd quarter. Ieq Capital LLC now owns 341,782 shares of the medical equipment provider’s stock worth $5,451,000 after buying an additional 66,821 shares during the period. Institutional investors and hedge funds own 84.61% of the company’s stock.
NovoCure Price Performance
Shares of NASDAQ:NVCR opened at $11.83 on Wednesday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.34 and a current ratio of 2.49. The stock has a 50 day moving average price of $14.84 and a 200-day moving average price of $14.75. The firm has a market capitalization of $1.38 billion, a P/E ratio of -11.16 and a beta of 1.09. NovoCure has a 52-week low of $9.82 and a 52-week high of $21.45.
NovoCure (NASDAQ:NVCR – Get Free Report) last released its earnings results on Thursday, October 29th. The medical equipment provider reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.14. The firm had revenue of $193.40 million for the quarter, compared to analysts’ expectations of $182.28 million. NovoCure had a negative return on equity of 35.81% and a negative net margin of 16.78%. The company’s quarterly revenue was up 15.7% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.33) earnings per share. As a group, equities research analysts anticipate that NovoCure will post -1.10 EPS for the current fiscal year.
NovoCure Company Profile
NovoCure is a global oncology company that develops and commercializes Tumor Treating Fields (TTFields), a cancer treatment that uses wearable devices to deliver low-intensity electric fields intended to disrupt cancer cell division. Its products include Optune Gio and Optune Lua, which are used to treat certain cancers. The company is headquartered in Baar, Switzerland, and serves patients in markets across North America, Europe and Asia. NovoCure was founded in 2000 by Yoram Palti, a medical researcher who developed the TTFields approach.
See Also
- Five stocks we like better than NovoCure
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for NovoCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovoCure and related companies with MarketBeat.com's FREE daily email newsletter.
